Fujian Haixi Pharmaceuticals (HKG:2637) obtained approval for an investigational new drug application for a clinical trial of HXP089.
The drug has been developed by the company to treat glioblastoma, according to a Tuesday Hong Kong bourse filing.
Fujian Haixi Pharmaceuticals (HKG:2637) obtained approval for an investigational new drug application for a clinical trial of HXP089.
The drug has been developed by the company to treat glioblastoma, according to a Tuesday Hong Kong bourse filing.
Comments